New Zealanders Can Now Access Funded OPDIVO® (Nivolumab) For Previously Treated Metastatic Renal Cell Carcinoma
This OPDIVO funding marks the first kidney cancer medicine decision following the New Zealand Government’s funding boost announced June 2024.